Skip to main content
Clinical Trials/DRKS00026205
DRKS00026205
Recruiting
未知

Predictive relevance of genetic polymorphisms in the glycogen-synthase-kinase-3beta (GSK3B) mediated intracellular signal transduction for the efficacy of lithium augmentation of antidepressants in the treatment-resistant major depression - ALIA

Charité - Universitätsmedzin Berlin0 sites500 target enrollmentSeptember 14, 2021

Overview

Phase
未知
Intervention
Not specified
Conditions
F32
Sponsor
Charité - Universitätsmedzin Berlin
Enrollment
500
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 14, 2021
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Charité - Universitätsmedzin Berlin

Eligibility Criteria

Inclusion Criteria

  • unipolar major depression
  • \-indication for antidepressant pharmacotherapy
  • \-HAMD\-17 \= 12
  • \-Inadequate response to antidepressant monotherapy and indication for lithium augmentation.
  • \-Minimum age: 18 years
  • \-physician\-confirmed capacity to consent
  • \-written informed consent
  • \-No participation in an AMG study (1 month prior) and during study participation.

Exclusion Criteria

  • \-psychotic symptoms, current
  • \-Contraindication to lithium therapy (e.g. severe renal insufficiency, pathological TSH or relevant ECG changes) \- for a list of contraindications, see the technical information in the appendix.
  • \-laboratory values and/or ECG findings that speak against taking lithium
  • \-depressive syndrome due to a non\-psychiatric or in the context of a further axis I diagnosis
  • \-diagnosis of dementia or organic brain disease
  • \-Diagnosis of substance dependence and use of the substance in the last 6 months (except caffeine and nicotine)
  • \-Diagnosis of an antisocial personality disorder

Outcomes

Primary Outcomes

Not specified

Similar Trials